PBIOClinical Trials•globenewswire•
Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108
Sentiment:Positive (85)
Summary
PALI-2108 demonstrated to be safe and well tolerated with no serious adverse events (SAEs)
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 7, 2025 by globenewswire